Risk Management Best Practices for Clinical Laboratories: A Practical Guide

Effective risk management protects patients, personnel, and data while sustaining reliable turnaround times and regulatory compliance. This guide translates best practices into clear, practical actions you can implement across the Pre-analytical Phase, Analytical Phase, and Post-analytical Phase of your laboratory workflow.

Risk Management Process Overview

Purpose and scope

Your goal is to anticipate failures before they cause harm, then reduce their likelihood and impact with targeted controls. Define scope to include the entire testing lifecycle—from specimen collection to result reporting—and the interfaces with clinicians, IT, supply chain, and waste management.

Core steps

• Establish context: objectives, risk criteria, and tolerance.
• Identify hazards and failure modes across the Pre-analytical, Analytical, and Post-analytical phases.
• Analyze and evaluate risks using Failure Modes and Effects Analysis (FMEA) and the Risk Priority Number (RPN).
• Treat risks with controls, verify effectiveness, and document decisions.
• Monitor performance, investigate events, and drive continual improvement.

Governance and documentation

Assign ownership to a cross-functional committee, maintain version-controlled records of assessments and actions, and integrate change control so new methods, instruments, or LIS updates undergo review before go-live.

Conducting Risk Assessments

Map the workflow

Start by diagramming each step and handoff: order entry, collection, transport, accessioning, preparation, analysis, verification, and result communication. Note dependencies such as reagents, equipment, interfaces, and staffing.

Identify failure modes with FMEA

Use Failure Modes and Effects Analysis (FMEA) to list where and how each step might fail, why it could happen, and the potential effects. Examples include mislabeling during the Pre-analytical Phase, instrument drift in the Analytical Phase, or delayed critical value notification in the Post-analytical Phase.

Prioritize using the Risk Priority Number (RPN)

Score each failure mode for Severity, Occurrence, and Detectability on consistent scales (for example, 1–10). Calculate the Risk Priority Number (RPN) as Severity × Occurrence × Detectability, then rank issues to focus on the highest priorities first.

Integrate Biological Risk Assessment

For pathogens and biological materials, perform a Biological Risk Assessment considering agent characteristics, procedures, exposure routes, and personnel susceptibility. Align controls with the hierarchy of controls and appropriate containment practices.

Use evidence and iterate

Calibrate scores with incident data, proficiency testing findings, QC trends, and audit results. Reassess after implementing controls to confirm risk reduction and update documentation accordingly.

Forming a Risk Assessment Team

Essential roles

• Laboratory director or designee to set risk criteria and approve mitigations.
• Quality manager to facilitate FMEA, trend data, and oversee documentation.
• Biosafety or safety officer to guide Biological Risk Assessment and exposure control.
• Section supervisors and front-line technologists to provide process realities and practical solutions.
• IT/LIS specialist to address interfaces, barcoding, decision support, and data integrity.
• Specimen collection, nursing, or phlebotomy representatives to close Pre-analytical gaps.
• Supply chain or equipment engineering support for reliability and maintenance risks.

Engagement model

Define responsibilities, meeting cadence, and escalation paths. Use a simple RACI for each mitigation so ownership is unambiguous and timelines are tracked to completion.

Implementing Risk Mitigation Strategies

Apply the hierarchy of controls

• Elimination/substitution: retire unstable assays or adopt safer reagents.
• Engineering controls: biosafety cabinets, sealed rotors, interlocks, and physical segregation of steps.
• Administrative controls: standardized SOPs, checklists, independent verifications, and workload balancing.
• PPE: appropriate gloves, face/eye protection, and gowns as a last line of defense.

Embed process and digital safeguards

• Specimen identity: barcoding, two-identifier checks, and positive patient identification.
• Analytical reliability: preventive maintenance, calibration verification, delta checks, and autoverification with rule-based limits.
• Post-analytical integrity: reflex/reflective testing rules, critical value alerts, and read-back verification.

Human factors and training

Design workspaces and workflows to reduce cognitive load. Use competency assessments, simulation drills, and error-proofing (poka‑yoke) to make the right action the easy action.

Contingency and resilience

Create playbooks for instrument downtime, reagent shortages, and IT outages. Define minimum service levels, backup methods, and communication plans so you can maintain patient care during disruptions.

Developing a Quality Control Plan

Risk-based QC design

Let your FMEA drive the Quality Control Plan. Increase QC frequency or tighten rules where Severity or Occurrence is high, and add additional detectability checks where Detectability is low.

Quality Assurance Activities and monitoring

Integrate Quality Assurance Activities such as internal audits, proficiency testing reviews, lot-to-lot verification, method comparisons, and document control. Trend Levey‑Jennings charts, apply appropriate Westgard rules, and set clear criteria for troubleshooting and release.

Controls across all phases

• Pre-analytical Phase: collection guides, transport stability checks, rejection criteria, and specimen adequacy metrics.
• Analytical Phase: calibration schedules, QC materials spanning decision points, and instrument performance KPIs.
• Post-analytical Phase: result verification rules, critical result workflows, and timely, accurate report delivery.

Utilizing Biorisk Management Models

Core components

• Risk identification: agent risk groups, procedure risks, facility and equipment constraints.
• Risk evaluation: likelihood–consequence analysis tailored to your procedures.
• Risk control: engineering solutions, administrative measures, PPE, waste handling, and decontamination.
• Preparedness: spill response, exposure management, inventory controls, and secure storage.

Operational integration

Embed biorisk practices into daily routines: pre-task risk checks, supervisor sign-off for high-risk manipulations, and periodic challenges of emergency procedures. Align training, drills, and maintenance with identified biological hazards.

Emphasizing Continuous Improvement

Measure what matters

Track leading and lagging indicators: near misses, specimen rejection rates, QC rule violations, turnaround times, and notification timeliness. Make data visible with dashboards reviewed in routine huddles.

From events to learning

Investigate deviations with root cause analysis, implement corrective and preventive actions (CAPA), and verify effectiveness. Feed lessons back into your FMEA and Quality Control Plan to steadily lower risk.

Manage change deliberately

Use change control for new tests, software updates, and layout changes. Require risk review, validation evidence, training, and go-live checklists to prevent unintended consequences.

FAQs.

What are the key steps in the risk management process for clinical laboratories?

Define scope and risk criteria, identify hazards across the Pre-analytical, Analytical, and Post-analytical phases, analyze and evaluate risks with FMEA, prioritize using RPN, implement targeted controls, verify effectiveness, document decisions, and monitor results for continuous improvement.

How is the risk priority number (RPN) calculated and used?

RPN equals Severity × Occurrence × Detectability. You score each factor on a consistent scale, multiply to get the RPN, and then rank failure modes so you focus first on the highest-risk items and choose mitigations that meaningfully reduce one or more components.

Who should be included in the risk assessment team?

Include the lab director, quality manager, biosafety or safety officer, section supervisors, front-line technologists, IT/LIS support, representatives for specimen collection, and supply or equipment specialists. Add clinicians or other stakeholders as needed for high-impact processes.

How often should risk assessments be conducted and updated?

Perform a comprehensive assessment at least annually and update it whenever significant changes occur—new methods, instruments, software, staffing models, or facilities—or when metrics, incidents, or audits indicate emerging risks.